Antiemetic Drug Market size is set to grow by USD 1632.81 mn from 2023-2027, rising geriatric population globally to boost the market growth, Technavio

NEW YORK, May 15, 2024 /PRNewswire/ -- The global antiemetic drug market  size is estimated to grow by USD 1632.81 mn from 2023-2027, according to Technavio. The market is estimated to grow at a CAGR of  6.47%  during the forecast period. 

For more insights on the forecast market size and historic data (2017 - 2021) - Download Free sample report in a minutes 

Key Market Trends Fueling Growth

The antiemetic drug market is witnessing significant growth due to the integration of digital health solutions. Telehealth platforms facilitate remote monitoring and management of symptoms related to nausea and vomiting, enabling timely interventions for patients. Antiemetic drugs, including antihistamines and anticholinergics, are utilized in various medical conditions such as post-operative surgery, cancer cases, and gastroenteritis. These drugs are available in hospital pharmacies, online pharmacies, and retail outlets. The market includes a diverse range of products like Gravisetron, Barhemsys, Ondansetron (Zofran), and Chemotherapy. Digital platforms are revolutionizing antiemetic drug management, enhancing patient convenience and reducing healthcare expenditure. 

Market Challenges

• The antiemetic drug market faces significant challenges due to the side effects and safety concerns of these medications. Antiemetics are essential for managing nausea and vomiting, but they can cause drowsiness, dizziness, constipation, and dry mouth. These side effects can negatively impact a patient's daily activities, quality of life, and treatment adherence. For instance, sedating antiemetics may limit a patient's ability to drive or operate machinery. Antiemetics are used to treat various conditions, including gastroenteritis, cancer, and postoperative surgery. Side effects can also result from serotonin receptor antagonists, neurokinin receptor antagonists, general anesthetics, opioid analgesics, and certain chemotherapies. Other causes of nausea and vomiting include food poisoning, emotional stress, metabolic disorders, and dehydration. Esophageal tears can also lead to vomiting. Antiemetics play a crucial role in managing these ailments, but their side effects must be carefully monitored and managed.

Research report provides comprehensive data on impact of trend, driver and challenges - Buy Report

Segment Overview 

This antiemetic drug market report extensively covers market segmentation by

1. Drug Class
• 1.1 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist
• 1.2 Dopamine antagonist
• 1.3 Neurokinin-1 (NK 1) receptor antagonist
• 1.4 Cannabinoid receptor antagonist
• 1.5 Others
2. Application 
• 2.1 Chemotherapy
• 2.2 Surgery
• 2.3 Gastroenteritis
• 2.4 Others
3. Geography 
• 3.1 North America
• 3.2 Europe
• 3.3 Asia
• 3.4 Rest of World (ROW)

1.1 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist-  The antiemetic drug market is segmented based on drug class, with 5-HT3 receptor antagonists holding a significant share due to their efficacy in managing nausea and vomiting caused by motion sickness, chemotherapies, and other side effects. Dopamine receptor antagonists and neurokinin receptor antagonists are other prominent classes, used in treating dizziness associated with motion sickness and chemotherapy-induced nausea and vomiting, respectively. Market segments include motion sickness, chemotherapies, side effects, food poisoning, emotional stress, cancer statistics, metabolic disorders, dehydration, nutritional depletion, esophageal tears, and treatment schedules. Patent expiration and dosage strength influence usage and healthcare expenditure. Drug types encompass antihistamines, anticholinergics, and 5-HT3 receptor antagonists. Applications span post-operative surgery, hospital pharmacies, and online pharmacies. Key drug brands include Gravisen, used in surgical procedures and cancer cases, and various antiemetic drugs used during chemotherapies, surgeries, and radiation therapy. The market's growth is driven by the increasing number of cancer cases and surgeries, as well as the raw material estimations for antiemetic drug production.

For more information on market segmentation with geographical analysis including forecast (2023-2027) and historic data (2017 - 2021)  - Download a Sample Report

Research Analysis

The Antiemetic Drug Market encompasses a wide range of medications used to prevent and alleviate nausea, vomiting, and other symptoms associated with various ailments, including gastroenteritis caused by viruses like rotavirus, as well as side effects from chemotherapies and vertigo. Antiemetic drugs, also known as antiemetics or antiemesis medications, function as serotonin receptor antagonists, such as Ondansetron and Granisetron, produced by various pharmaceutical companies. These drugs are readily available at retail pharmacies, including CVS Pharmacy, Walgreens Boots Alliance, and Rite Aid, providing essential relief for individuals experiencing nausea, emesis, and motion sickness. Cumberland Pharmaceuticals and Sancuso are notable contributors to the market, while Sandoz and other generic substitutes offer affordable alternatives for patients.

Market Research Overview

The Antiemetic Drug Market encompasses a range of pharmacological treatments designed to prevent and alleviate nausea and vomiting. These drugs are essential in managing side effects of chemotherapy, radiation therapy, and surgical procedures. The market is driven by the increasing prevalence of diseases requiring antiemetic therapy, such as cancer and gastrointestinal disorders. Additionally, advancements in technology and research have led to the development of novel antiemetic agents, expanding the market's scope. The market also faces challenges, including drug resistance and adverse effects, necessitating continuous innovation and improvement. Overall, the Antiemetic Drug Market is a significant and evolving sector in the healthcare industry.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

• Drug Class
• 5-Hydroxytryptamine 3 (5-HT 3) Receptor Antagonist
• Dopamine Antagonist
• Neurokinin-1 (NK 1) Receptor Antagonist
• Cannabinoid Receptor Antagonist
• Others
• Application
• Chemotherapy
• Surgery
• Gastroenteritis
• Others
• Geography
• North America
• Europe
• Asia
• Rest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio